靶向 HER2 的药物有 Afatinib、Lapatinib (拉帕替尼)、Neratinib(来那替尼) 等。经典的 HER2 抑制剂Afatinib是不可逆的 EGFR 家族抑制剂，抑制 EGFR WT，EGFR L858R，EGFR L858R/T790M 和 HER2 的 IC50分别为 0.5 nM，0.4 nM，10 nM 和 14 nM; FDA approvedLapatinibHER2 和 EGFR 酪氨酸激酶结构域的有效...
Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, et al. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 2007;143:20-26.Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP...
Dr. Gainor:IMpower151的开展紧跟在IMpower150之后,区分这两项研究很重要。IMpower150是一项探索卡铂/紫杉醇/贝伐珠单抗+/-阿替利珠单抗方案的随机III期研究,该研究在无进展生存(PFS)和总生存(OS)方面均为阳性。IMpower151在以下几个方面与IMpower150有所不同。首先,IMpower151是一项比较卡铂+培美曲塞或紫杉醇(尽管...
[14] Dong ZY, Zhang JT, Liu SY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017;6:e1356145. [15] Gainor JF, Shaw AT, Sequist LV, et al. EGFR Mutations an...
首页 / 癌基因 / EGFR / Gain-of-functionEGFR(epidermal growth factor receptor) EGFR编码的蛋白是一种跨膜糖蛋白,也是表皮生长因子受体家族中的一员,该家族包括HER1(erbB1,EGFR)、HER2(erbB2,NEU)、HER3(erbB3)及HER4(erbB4),也属于受体酪氨酸激酶家族。EGFR作为细胞表面蛋白可与配体如表皮生长因子(EGF)...
[2]. Gainor J, Shaw A. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J clin oncol. 2013;31:3987–96. doi: 10.1200/JCO.2012.45.2029. [3].Lim ZF, Ma PC. Emerg...
摘要：头颈部恶性肿瘤是世界上第七大常见的癌症类型。超过90%的头颈部恶性肿瘤是鳞状细胞癌（HN⁃SCC）。放疗是HNSCC的重要治疗方法之一，肿瘤细胞对放疗的敏感性是放疗有效性的一个关键因素。p53是HN⁃SCC中最常见的突变基因之一，表皮生长因子受体（EGFR）在许多的HNSCC中过度表达，这两者都能增强细胞DNA 的修复...
Identification of p53 accumulation, EGFR gain and PDGFRα gain/amplification as adverse prognostic factors in pediatric high grade gliomas – evaluation of... Identification of p53 accumulation, EGFR gain and PDGFRα gain/amplification as adverse prognostic factors in pediatric high grade gliomas – ...
(p=0.01). EGFR gain (21%) could be correlated highly significant to shorter OS (p<0.001) and significant to shorter event-free survival (EFS) in this group (p=0.042). By immunohistochemistry we found an accumulation of p53 gene product in 20/70 samples (28.6%). In infant HGG patients...
However, acquired drug resistance against osimertinib occurs inevitably through either gain of new genetic mutations such as C797S, MET, and other gene amplifications, and lineage transformation to small cell or squamous cell lung cancer [33,34,35]. Drug-tolerant persister cells (DTPCs) are a ...